Inverse agonists – What do they mean for psychiatry?

European Neuropsychopharmacology

Volumn 27, Issue 1, 2017, Pages 87-90

  Nutt, David ^a   Stahl, Stephen ^b   Blier, Pierre ^c   Drago, Filippo ^d   Zohar, Joseph ^e   Wilson, Sue ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROYAL OTTAWA HOSPITAL   (Canada)

^d UNIVERSITY OF CATANIA   (Italy)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

5 HT2A; Antagonist; Inverse agonist; Serotonin

Indexed keywords

CALCIUM CHANNEL; PIMAVANSERIN; SEROTONIN 2A RECEPTOR; PIPERIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST; UREA;

AGONIST; ARTICLE; CLINICAL TRIAL (TOPIC); DEPRESSION; DOWN SYNDROME; HUMAN; INVERSE AGONISM; MEMORY DISORDER; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOSIS; ANALOGS AND DERIVATIVES; ANIMAL; MENTAL DISEASE;

ANIMALS; HUMANS; MENTAL DISORDERS; PIPERIDINES; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; UREA;

EID: 85007597370     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.11.013     Document Type: Article

References (15)

1. Al-Shamma, H.A., Anderson, C., Chuang, E., et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J. Pharmacol. Exp. Ther. 332 (2010), 281–290.
2. Charig, E.M., Anderson, I.M., Robinson, J.M., et al. L-Tryptophan and prolactin release: evidence for an interaction between 5-HT and 5-HT2 receptors. Hum. Psychopharmacol. 1 (1986), 93–97.
3. Cummings, J., Isaacson, S., Mills, R., et al. Pimavanserin for patients with Parkinson׳s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383 (2014), 533–540.
4. File, S.E., Lister, R.G., Nutt, D.J., The anxiogenic action of benzodiazepine antagonists. Neuropharmacology 21 (1982), 1022–1037.
5. Idzikowski, C., Cowen, P.J., Nutt, D.J., et al. The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology 93 (1987), 416–420.
6. Kenakin, T., Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65 (2004), 2–11.
7. Landolt, H.P., Wehrle, R., Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?. Eur. J. Neurosci. 29 (2009), 1795–1809.
8. Meltzer, H.Y., Elkis, H., Vanover, K., Weiner, D.M., van Kammen, D.P., Peters, P., Hacksell, U., Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day. Schizophr. Res. 141:2–3 (2012), 144–152.
9. Muntasir, H.A., Bhuiyan, M.A., Ishiguro, M., et al. Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor. J. Pharmacol. Sci. 102 (2006), 189–195.
10. Nutt, D.J., Besson, M., Wilson, S.J., et al. Blockade of alcohol׳s amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 53 (2007), 810–820.
11. Nutt, D.J., Cowen, P.C., Little, H.J., Unusual interactions of benzodiazepine receptor antagonists. Nature 295 (1982), 436–438.
12. Nutt, D.J., Linnoila, M., Neuroreceptor science: a clarification of terms. J. Clin. Psychopharmacol. 8 (1988), 387–389.
13. Nyberg, S., Eriksson, B., Oxenstierna, G., et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am. J. Psychiatry 156 (1999), 869–875.
14. Vanover, K.E., Weiner, D.M., Makhay, M., et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 317 (2006), 910–918.
15. Weiner, D.M., Burstein, E.S., Nash, N., et al. 5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 299 (2001), 268–276.